Business Wire

Mavacamten Demonstrated Significant Reduction in Need for Septal Reduction Therapy in Symptomatic Obstructive HCM Patients in Phase 3 VALOR Trial

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced results from the Phase 3 VALOR-HCM study, which showed the addition of mavacamten, an investigational, first-in-class ...
Healio

Primary TAVR may be best strategy for aortic stenosis causing cardiogenic shock

Please provide your email address to receive an email when new articles are posted on . Transcatheter aortic valve replacement is safe and effective in people with aortic stenosis and cardiogenic ...